Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Pharmacogenetics of chronic heart failure--beta blockers].

Casopis lekaru ceskych - 1 Jan 2006

Vasků A, Spinarová L, Pávková-Goldbergová M, Spinar J, Soucek M, Vítovec J

Abstract excerpt

BACKGROUND: Activation of the renin-angiotensin (RAS) cascade and sympathetic nervous systems adversely affect heart failure progression. ACE deletion allele (ACE D) of insertion/deletion polymorphism in the gene coding for angiotensin-1 converting enzyme is associated with increased renin-angiotensin activation. The aim of the study was to test pharmacogenetic associations of I/D ACE genotype with beta blockers...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenergic beta-Antagonists
Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Frequency

Share to Genotype

Share to Heart Failure

Share to Peptidyl-Dipeptidase A

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 16521406

Genes

ACE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Pharmacogenetics of chronic heart failure--beta blockers].PMID 16521406Read ↗

[Adrenergic receptor polymorphisms in heart failure: what can genetics explain?].Semantic proximity Read ↗

Gene polymorphism of angiotensin-converting enzyme and angiotensin II type 1 receptor in patients with congestive heart failure.Semantic proximity Read ↗

[Effect of the polymorphism of the angiotensin-converting enzyme gene on the drug treatment in patients with chronic heart failure].Semantic proximity Read ↗

[Pharmacogenomic control of angiotensin converting enzyme gene I/D polymorphism predominant risk factor of development of chronic heart failure and target of enalapril treatment].Semantic proximity Read ↗

Beta-adrenergic receptor blockade and the angiotensin-converting enzyme deletion polymorphism in patients with chronic heart failure.Semantic proximity Read ↗

[Effect of the polymorphism of the angiotensin-converting enzyme gene on the plasma angiotensin II levels and the risk of chronic heart failure].Semantic proximity Read ↗

The future of pharmacogenetics in the treatment of heart failure.Semantic proximity Read ↗

Pharmacogenetics of heart failure: evidence, opportunities, and challenges for cardiovascular pharmacogenomics.Semantic proximity Read ↗

[I/D angiotensin-converting enzyme gene polymorphism: structural changes in the myocardium and predictive value in chronic heart failure].Semantic proximity Read ↗

Influence of Angiotensin-Converting-Enzyme Gene Polymorphism on Echocardiographic Data of Patients with Ischemic Heart Failure.Semantic proximity Read ↗

[ACE gene polymorphism and cardiovascular diseases].Semantic proximity Read ↗

Association of the angiotensin-converting enzyme gene polymorphism with chronic heart failure in Chinese Han patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.